Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SB Augmentin Composition Patent May Protect U.S. Sales Until 2017

Executive Summary

A formulation patent issued for SmithKline Beecham's flagship antibiotic Augmentin may protect the U.S. market for the product until 2017.

You may also be interested in...



GSK Formula For Older Products: "Clever" Patent Defenses, Cutting SKUs

GlaxoSmithKline's next phase of global streamlining will focus on reducing the number of formulations of older brands that it produces.

GSK Formula For Older Products: "Clever" Patent Defenses, Cutting SKUs

GlaxoSmithKline's next phase of global streamlining will focus on reducing the number of formulations of older brands that it produces.

GSK Augmentin ES Needs "Boundary" On Resistant Strains Covered, FDA Cmte

GlaxoSmithKline should indicate an upper "boundary" of penicillin resistance that its antibiotic Augmentin ES is expected to effectively treat, FDA's Anti-Infective Drugs Advisory Committee suggested Jan. 30.

UsernamePublicRestriction

Register

ID1122310

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel